Log in
NASDAQ:EVOK

Evoke Pharma Stock Forecast, Price & News

$4.92
+0.11 (+2.29 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.75
Now: $4.92
$4.93
50-Day Range
$3.67
MA: $4.82
$5.70
52-Week Range
$0.73
Now: $4.92
$6.06
Volume184,196 shs
Average Volume356,984 shs
Market Capitalization$127.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Read More
Evoke Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.18 per share

Profitability

Net Income$-7,130,000.00

Miscellaneous

Employees6
Market Cap$127.97 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$4.92
+0.11 (+2.29 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

How has Evoke Pharma's stock been impacted by COVID-19?

Evoke Pharma's stock was trading at $1.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVOK stock has increased by 343.2% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Evoke Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evoke Pharma
.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Evoke Pharma
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) released its quarterly earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.20.
View Evoke Pharma's earnings history
.

What price target have analysts set for EVOK?

1 brokers have issued 1-year target prices for Evoke Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Evoke Pharma's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 103.3% from the stock's current price.
View analysts' price targets for Evoke Pharma
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 688,500 shares, an increase of 14.4% from the July 30th total of 601,700 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is currently 0.4 days. Approximately 3.0% of the shares of the stock are sold short.
View Evoke Pharma's Short Interest
.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the following people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.14%).
View institutional ownership trends for Evoke Pharma
.

Which major investors are buying Evoke Pharma stock?

EVOK stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc..
View insider buying and selling activity for Evoke Pharma
.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $4.92.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $127.97 million. The specialty pharmaceutical company earns $-7,130,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is www.evokepharma.com.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.